M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
UK-based biotechnology company Xenova Group Plc has been granted fast track review status by the US Food and Drug Administration (FDA).
The decision applies to tariquidar, Xenova's multi-drug resistant treatment for non-small cell lung cancer. Fast track status means that the FDA will facilitate the development and expedite the review of the new drug.
Tariquidar is reportedly the only product being developed that could be used to treat lung …